Physician profile
Stephen Stahl
NPI 1710144167
$1,409,281.15
in general payments reported to CMS, 2019-2025
31 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544K · 2020: $543K · 2021: $91K · 2022: $47K · 2023: $107K · 2024: $48K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $70K · Travel and Lodging: $24K · Honoraria: $16K · Food and Beverage: $2,873 · Education: $49.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,122.00 |
| Consulting Fee | $69,956.78 |
| Travel and Lodging | $24,144.25 |
| Honoraria | $16,475.00 |
| Food and Beverage | $2,873.24 |
| Education | $49.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $435,246.44 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $382,230.30 | 2019 | |
| H. Lundbeck A S | $72,211.63 | 2019-2023 | Brintellix, Escitalopram, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66,315.56 | 2022-2024 | Caplyta |
| Alkermes, INC. | $60,365.12 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| Acadia Pharmaceuticals INC | $58,629.00 | 2019-2025 | Acp-204, Nuplazid |
| Abbvie INC. | $46,866.37 | 2021-2023 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $42,855.89 | 2019-2022 | |
| Allergan, INC. | $35,328.00 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $28,828.64 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $22,710.81 | 2019-2023 | Rexulti |
| Cipla USA INC. | $20,000.00 | 2021 | |
| Sage Therapeutics, LLC | $19,144.14 | 2019-2022 | |
| Janssen Research & Development, LLC | $17,877.70 | 2019 | |
| Daiichi Sankyo Company Ltd | $15,000.00 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13,039.18 | 2021-2024 | Rexulti |
| Tris Pharma INC | $11,500.00 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $11,398.48 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $10,894.84 | 2021-2025 | Qelbree |
| Pfizer INC. | $9,780.81 | 2019 | |
| Livanova USA, INC. | $6,108.88 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Upjohn US 1 LLC | $4,500.00 | 2019 | |
| Axsome Therapeutics, INC. | $4,321.89 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $4,165.00 | 2020 | |
| Merck Sharp & Dohme LLC | $3,720.00 | 2021-2022 | |
| Neos Therapeutics, Lp | $2,375.00 | 2025 | Exxua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,780.00 | 2025 | |
| Bausch Health US, LLC | $1,000.00 | 2020 | |
| Eli Lilly and Company | $500.00 | 2019 | |
| Biomarin Pharmaceutical INC. | $491.78 | 2023 | |
| Eisai INC. | $95.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Stahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.